Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 9, 2015, Pages 1079-1095

  Streiff, Michael B ^a   Holmstrom, Bjorn ^b   Ashrani, Aneel ^c   Bockenstedt, Paula L ^d   Chesney, Carolyn ^e   Eby, Charles ^f   Fanikos, John ^g   Fenninger, Randolph B ^h   Fogerty, Annemarie E ⁱ   Gao, Shuwei ^j   Goldhaber, Samuel Z ^g   Hendrie, Paul ^k   Kuderer, Nicole ^k   Lee, Alfred ^l   Lee, Jason T ^m   Lovrincevic, Mirjana ⁿ   Millenson, Michael M ^o   Neff, Anne T ^p   Ortel, Thomas L ^q   Paschal, Rita ^r   Shattil, Sanford ^s   Siddiqi, Tanya ^t   Smock, Kristi J ^u   Soff, Gerald ^v   Wang, Tzu Fei ^w   Yee, Gary C ^x   Zakarija, Anaadriana ^y   McMillian, Nicole ^z   Engh, Anita M ^z   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f BARNES JEWISH HOSPITAL   (United States)

^g Dana Farber Brigham and Women's Cancer Center   (United States)

^h National Blood Clot Alliance   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k SEATTLE CANCER CARE ALLIANCE   (United States)

^l YALE CANCER CENTER   (United States)

^m STANFORD CANCER INSTITUTE   (United States)

ⁿ ROSWELL PARK CANCER INSTITUTE   (United States)

^o FOX CHASE CANCER CENTER   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

^q DUKE CANCER INSTITUTE   (United States)

^r UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^s UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^t CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^u UNIVERSITY OF UTAH   (United States)

^v MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^w OHIO STATE UNIVERSITY   (United States)

^x UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^y NORTHWESTERN UNIVERSITY   (United States)

^z National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; WARFARIN; ANTICOAGULANT AGENT; POLYSACCHARIDE;

ACCREDITATION; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BARIATRIC SURGERY; BLOOD VOLUME; BODY WEIGHT; CANCER ASSOCIATED VENOUS THROMBOEMBOLIC DISEASE; CONTINUING EDUCATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HOSPITAL PATIENT; HUMAN; OBESITY; OUTPATIENT; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TUMOR THROMBUS; BODY MASS; CHRONIC KIDNEY FAILURE; COMPLICATION; NEOPLASM; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; BODY MASS INDEX; BODY WEIGHT; DALTEPARIN; ENOXAPARIN; HEPARIN; HUMANS; NEOPLASMS; OBESITY; POLYSACCHARIDES; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; VENOUS THROMBOEMBOLISM;

EID: 84941770097     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0133     Document Type: Article

References (108)

1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-490.
2. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
3. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013;119:648-655.
4. Kakkar AK, Levine M, Pinedo HM, et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003;8:381-388.
5. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-394.
6. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936-945.
7. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464.
8. Chew HK, Wun T, Harvey DJ, et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-76.
9. Kuderer NM, Francis CW, Culakova E, et al. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 9521.
10. Martino MA, Williamson E, Siegfried S, et al. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol 2005;98:289-293.
11. Sorensen H T, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
12. Bessesen DH. Update on obesity. J Clin Endocrinol Metab 2008;93:2027-2034.
13. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. NCHS Data Brief 2013:1-8.
14. Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr 2012;10:22.
15. O'Brien PE, Dixon JB. The extent of the problem of obesity. Am J Surg 2002;184:4S-8S.
16. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-781.
17. Boeing H. Obesity and cancer - The update 2013. Best Pract Res Clin Endocrinol Metab 2013;27:219-227.
18. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposityrelated cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst 2015;107.
19. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
20. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010;15:556-565.
21. Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 2015;16:36-46.
22. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Ovarian Cancer 2014: AICR; 2014. Available at: http://www.dietandcancerreport.org/cup/cup-resources.php. Accessed August 23, 2015.
23. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR; 2007. Available at: http://www.dietandcancerreport.org/cancer-resource-center/er-full-report-english. php. Accessed August 23, 2015.
24. CUP team, Imperial College London. Continuous update of the epidemiological evidence on food, nutrition, physical activity and the risk of gallbladder cancer: AICR; 2012. Available at: http://www.dietandcancerreport.org/cancer-resource-center/downloads/cu/CUP-gallbladder-cancer-protocol.pdf. Accessed August 23, 2015.
25. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-809.
26. Golabek T, Bukowczan J, Chlosta P, et al. Obesity and prostate cancer incidence and mortality: a systematic review of prospective cohort studies. Urol Int 2014;92:7-14.
27. Chen Y, Wang X, Wang J, et al. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer 2012;48:2137-2145.
28. Dobbins M, Decorby K, Choi BC. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013;2013:680536.
29. Castillo JJ, Ingham RR, Reagan JL, et al. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. Clin Lymphoma Myeloma Leuk 2014;14:122-130.
30. Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011;47:2422-2430.
31. Kitahara CM, Platz EA, Freeman LE, et al. Obesity and thyroid cancer risk among U. S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011;20:464-472.
32. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.
33. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-1248.
34. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-4907.
35. Olson NC, Cushman M, Judd SE, et al. American Heart Association's Life's Simple 7 and risk of venous thromboembolism: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. J Am Heart Assoc 2015;4:e001494.
36. Klovaite J, Benn M, Nordestgaard BG. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. J Intern Med 2015;277:573-584.
37. Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A timedependent analysis. Thromb Haemost 2012;108:508-515.
38. Olson NC, Cushman M, Lutsey PL, et al. Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost 2014;12:1993-2001.
39. Watts JL, Kuehnlenz D, Sulo S, et al. Common characteristics of patients diagnosed with upper-extremity venous thromboembolism during hospitalization: a descriptive study. Clin Nurse Spec 2015;29:48-54.
40. Sartori M, Migliaccio L, Favaretto E, et al. Tw o years outcome of isolated distal deep vein thrombosis. Thromb Res 2014;134:36-40.
41. Hansen JB, Fernandez JA, Borch KH, et al. Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. Thromb Res 2012;129:502-507.
42. Hicks LK, Cheung MC, Ding K, et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 2009;115:5516-5525.
43. Tsai J, Grant AM, Beckman MG, et al. Determinants of venous thromboembolism among hospitalizations of US adults: a multilevel analysis. PLoS One 2015;10:e0123842.
44. Wu XS, Wu WG, Li ML, et al. Impact of being overweight on the surgical outcomes of patients with gastric cancer: a meta-analysis. World J Gastroenterol 2013;19:4596-4606.
45. Childs BR, Nahm NJ, Dolenc AJ, Vallier HA. Obesity is associated with more complications and longer hospital stays after orthopaedic trauma [published online ahead of print March 9, 2015]. J Orthop Trauma, in press.
46. Si HB, Zeng Y, Shen B, et al. The influence of body mass index on the outcomes of primary total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc 2015;23:1824-1832.
47. Day JS, Ramsey ML, Lau E, Williams GR. Risk of venous thromboembolism after shoulder arthroplasty in the Medicare population. J Shoulder Elbow Surg 2015;24:98-105.
48. Parvizi J, Huang R, Raphael IJ, et al. Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors. Clin Orthop Relat Res 2014;472:903-912.
49. Haskins IN, Amdur R, Sarani B, Vaziri K. Congestive heart failure is a risk factor for venous thromboembolism in bariatric surgery [published online ahead of print December 24, 2014]. Surg Obes Relat Dis. doi: 10.1016/j. soard.2014.12.020.
50. Jamal MH, Corcelles R, Shimizu H, et al. Thromboembolic events in bariatric surgery: a large multi-institutional referral center experience. Surg Endosc 2015;29:376-380.
51. Chan MM, Hamza N, Ammori BJ. Duration of surgery independently influences risk of venous thromboembolism after laparoscopic bariatric surgery. Surg Obes Relat Dis 2013;9:88-93.
52. Robinson KA, O'Donnell ME, Pearson D, et al. Portomesenteric venous thrombosis following major colon and rectal surgery: incidence and risk factors. Surg Endosc 2015;29:1071-1079.
53. Liu Y, Gao Y, Wei L, et al. Peripherally inserted central catheter thrombosis incidence and risk factors in cancer patients: a double-center prospective investigation. Ther Clin Risk Manag 2015;11:153-160.
54. Leung A, Heal C, Perera M, Pretorius C. A systematic review of patientrelated risk factors for catheter-related thrombosis. J Thromb Thrombolysis 2015;40:363-373.
55. Blaivas M, Stefanidis K, Nanas S, et al. Sonographic and clinical features of upper extremity deep venous thrombosis in critical care patients. Crit Care Res Pract 2012;2012:489135.
56. Sankaralingam S, Kim RB, Padwal RS. The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control. Can J Cardiol 2015;31:167-176.
57. Velissaris D, Karamouzos V, Marangos M, et al. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review. J Clin Med Res 2014;6:227-233.
58. Al-Dorzi HM, Al Harbi SA, Arabi YM. Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. Curr Opin Infect Dis 2014;27:165-173.
59. Hall RG 2nd, Jean G W, Sigler M, Shah S. Dosing considerations for obese patients receiving cancer chemotherapeutic agents. Ann Pharmacother 2013;47:1666-1674.
60. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012;30:1553-1561.
61. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212-1220.
62. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003;90:547-548.
63. Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005;165:341-345.
64. Bickford A, Majercik S, Bledsoe J, et al. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg 2013;206:847-851, discussion 851-842.
65. Raftopoulos I, Martindale C, Cronin A, Steinberg J. The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc 2008;22:2384-2391.
66. Wang T F, Milligan PE, Wong CA, et al. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost 2014;111:88-93.
67. Ikesaka R, Delluc A, Le Gal G, Carrier M. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thromb Res 2014;133:682-687.
68. Vandiver JW, Ritz LI, Lalama JT. Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations [published online ahead of print May 17, 2015]. J Thromb Thrombolysis, in press.
69. Magee CJ, Barry J, Javed S, et al. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery. Surg Obes Relat Dis 2010;6:322-325.
70. Simoneau MD, Vachon A, Picard F. Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. Obes Surg 2010;20:487-491.
71. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19-24.
72. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005;15:1368-1374.
73. Rowan BO, Kuhl DA, Lee MD, et al. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 2008;18:162-166.
74. Simone EP, Madan AK, Tichansky DS, et al. Comparison of two lowmolecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 2008;22:2392-2395.
75. Steele KE, Canner J, Prokopowicz G, et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surg Obes Relat Dis 2015;11:672-683.
76. Celik F, Huitema AD, Hooijberg JH, et al. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-xa levels. Obes Surg 2015;25:628-634.
77. Rondina MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010;125:220-223.
78. Ludwig KP, Simons HJ, Mone M, et al. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother 2011;45:1356-1362.
79. Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target antifactor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 2012;87:740-743.
80. Singh K, Podolsky ER, Um S, et al. Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 2012;22:47-51.
81. Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008;4:625-631.
82. Becattini C, Agnelli G, Manina G, et al. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surg Obes Relat Dis 2012;8:108-115.
83. Stroh C, Birk D, Flade-Kuthe R, et al. Evidence of thromboembolism prophylaxis in bariatric surgery-results of a quality assurance trial in bariatric surgery in Germany from 2005 to 2007 and review of the literature. Obes Surg 2009;19:928-936.
84. Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 2003;13:249-253.
85. Miller MT, Rovito PF. An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg 2004;14:731-737.
86. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840.
87. Martinez L, Burnett A, Borrego M, et al. Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health Syst Pharm 2011;68:1716-1722.
88. Li Y, Chen Y, Liu X, et al. Metabolic syndrome and chronic kidney disease in a Southern Chinese population. Nephrology (Carlton) 2014;19:325-331.
89. Lin B, Shao L, Luo Q, et al. Prevalence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang province, Eastern China. BMC Nephrol 2014;15:36.
90. Khajehdehi P, Malekmakan L, Pakfetrat M, et al. Prevalence of chronic kidney disease and its contributing risk factors in southern Iran: a crosssectional adult population-based study. Iran J Kidney Dis 2014;8:109-115.
91. McMahon GM, Preis SR, Hwang SJ, Fox CS. Mid-adulthood risk factor profiles for CKD. J Am Soc Nephrol 2014;25:2633-2641.
92. Tsujimoto T, Sairenchi T, Iso H, et al. The dose-response relationship between body mass index and the risk of incident stage >/=3 chronic kidney disease in a general japanese population: the Ibaraki prefectural health study (IPHS). J Epidemiol 2014;24:444-451.
93. Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke 2015;46:157-163.
94. Bauer A, Limperger V, Nowak-Gottl U. End-stage renal disease and thrombophilia. Hamostaseologie 2015;35.
95. Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007;5:937-941.
96. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecularweight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43:1064-1083.
97. Deal EN, Hollands JM, Riney JN, et al. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis 2011;32:188-194.
98. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-775.
99. Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol 2012;68:757-765.
100. Kothari SN, Lambert PJ, Mathiason MA. Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. Am J Surg 2007;194:709-711.
101. Brasileiro AL, Miranda F Jr, Ettinger JE, et al. Incidence of lower limbs deep vein thrombosis after open and laparoscopic gastric bypass: a prospective study. Obes Surg 2008;18:52-57.
102. Khoursheed M, Al-Bader I, Al-Asfar F, et al. Therapeutic effect of lowmolecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery. Surg Laparosc Endosc Percutan Tech 2013;23:491-493.
103. Escalante-Tattersfield T, Tucker O, Fajnwaks P, et al. Incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Rouxen-Y gastric bypass. Surg Obes Relat Dis 2008;4:126-130.
104. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232:515-529.
105. Higa KD, Ho T, Boone KB. Laparoscopic Roux-en-Y gastric bypass: technique and 3-year follow-up. J Laparoendosc Adv Surg Tech A 2001;11:377-382.
106. Prystowsky JB, Morasch MD, Eskandari MK, et al. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. Surgery 2005;138:759-763; discussion 763-755.
107. McCullough PA, Gallagher MJ, Dejong AT, et al. Cardiorespiratory fitness and short-term complications after bariatric surgery. Chest 2006;130:517-525.
108. Vaziri K, Bhanot P, Hungness ES, et al. Retrievable inferior vena cava filters in high-risk patients undergoing bariatric surgery. Surg Endosc 2009;23:2203-2207.